Alnylam

Press Releases

Mar 26,2018
Summary ToggleAlnylam Receives European Medicines Agency PRIME Designation for Accelerated Assessment of Lumasiran, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1)
PDF Version
Mar 21,2018
Summary ToggleRegeneron and Alnylam Pharmaceuticals Announce Collaboration to Discover New Treatments for Nonalcoholic Steatohepatitis (NASH)
PDF Version
Mar 21,2018
Summary ToggleAlnylam to Webcast Presentation at 17th Annual Needham Healthcare Conference
PDF Version
Mar 14,2018
Summary ToggleAlnylam to Report New Clinical Results from the APOLLO Phase 3 Study of Patisiran at the 16th International Symposium on Amyloidosis
PDF Version
Mar 13,2018
Summary ToggleAlnylam Unveils Resources to ‘Bridge the Gap’ in Knowledge of Hereditary ATTR (hATTR) Amyloidosis Among Families at Risk
PDF Version
Mar 12,2018
Summary ToggleAlnylam Retains Global Rights to Lumasiran, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1)
PDF Version
Mar 06,2018
Summary ToggleAlnylam to Webcast Presentations at Upcoming March Investor Conferences
PDF Version
Feb 08,2018
Summary ToggleAlnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Period Activity
PDF Version
Feb 05,2018
Summary ToggleAlnylam to Webcast Presentations at Upcoming February Investor Conferences
PDF Version
Feb 01,2018
Summary ToggleAlnylam Announces FDA Acceptance of New Drug Application (NDA) and Priority Review Status for Patisiran, an Investigational RNAi Therapeutic for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
PDF Version
Feb 01,2018
Summary ToggleAlnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2017 Financial Results
PDF Version
Jan 25,2018
Summary ToggleAlnylam Announces EMA Acceptance of Marketing Authorisation Application (MAA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
PDF Version
Jan 07,2018
Summary ToggleAlnylam Announces 2018 Corporate Goals
PDF Version
Jan 07,2018
Summary ToggleAlnylam and Sanofi Enter into Strategic Restructuring of RNAi Therapeutics Rare Disease Alliance
PDF Version
Jan 04,2018
Summary ToggleAlnylam Expands Alnylam Act™ Program to Include No-Charge Third-Party Genetic Testing and Counseling for People at Risk for Acute Hepatic Porphyrias
PDF Version
Jan 02,2018
Summary ToggleAlnylam to Webcast Presentation at 36th Annual J.P. Morgan Healthcare Conference
PDF Version
Dec 28,2017
Summary ToggleAlnylam to Webcast Presentation at Goldman Sachs Healthcare CEOs Unscripted Conference
PDF Version
Dec 18,2017
Summary ToggleAlnylam and Sanofi Submit Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
PDF Version
Dec 15,2017
Summary ToggleFDA Lifts Clinical Hold on Fitusiran
PDF Version
Dec 12,2017
Summary ToggleAlnylam Completes Submission of New Drug Application to U.S. Food and Drug Administration (FDA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
PDF Version
Displaying 21 - 40 of 959 results
View all releases

Search

: (Common):

Price:
Change (%):
Volume:
Data as of
Copyright NASDAQ. Minimum 15 minutes delay
Learn More